Anthony Elias is an Oncology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1635 Aurora Ct
Aurora, CO 800452541
Telephone
720-848-0000Provider last certified this registry record 3 Mar 2026.
Clinical trials
- ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Sponsor: QuantumLeap Healthcare Collaborative
- Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
Sponsor: University of Colorado, Denver
- Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Sponsor: University of Colorado, Denver
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20251 payment
- Stemline Therapeutics Inc.Program year20255 payments
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
91.3%Aromatase Inhibitor63.3%Anastrozole71%Letrozole29%Part D≥39 patientsKinase inhibitor23.5%Imatinib Mesylate46%Sunitinib Malate21%Ibrance18%Verzenio16%Part D<11 patients+ 1 more class in this area
Nervous system
8.7%Opioid Agonist8.7%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2004–2026 per NIH RePORTER. The latest:
- NCI National Clinical Trials Network - Lead Academic Participating Site
University of Colorado Denver
FY2026$633,000UG1CA233324 - NCI National Clinical Trials Network - Lead Academic Participant Sites
University of Colorado Denver
FY2025$618,036UG1CA233324 - NCI National Clinical Trials Network - Lead Academic Participant Sites
University of Colorado Denver
FY2024$618,036UG1CA233324
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”